SOURCE: DOR BioPharma, Inc.

June 04, 2007 08:00 ET

DOR BioPharma to Participate in 5th Annual Biodefense Vaccines & Therapeutics Conference on Monday June 4th

MIAMI, FL--(Marketwire - June 4, 2007) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR," or the "Company"), today announced that it will present at the 5th annual Biodefense Vaccines and Therapeutics Conference in Washington on Monday June 4th, 2007. Robert N. Brey, Ph.D., Chief Scientific Officer, will make a presentation at 2:15 PM entitled "Development and early clinical testing of a vaccine against ricin toxin" and will discuss the latest progress and developments concerning RiVax™. The conference is being held at the Almas Temple Club, 1315 K Street, Washington, DC. The conference addresses the development of countermeasures against significant biothreats and brings together scientific and policy leaders in the field.

About RiVax™

RiVax™ is a vaccine that induces antibodies that inactivate ricin toxin in animals and humans. The vaccine has been shown to be safely tolerated in humans in a Phase I dose-escalating trial using doses as high as 100 micrograms. The modified subunit given three times intramuscularly did not result in any side effects associated with the activity of natural ricin toxin and induced antibodies against ricin toxin. The functional activity of the antibodies was confirmed by transferring serum globulins from the vaccinated individuals along with active ricin toxin to mice that subsequently survived exposure to ricin.

About Ricin Toxin

Ricin toxin is a potential bioterror threat due to its high toxicity in small doses, ease of production, and ability to be aerosolized. The need for protective countermeasures against ricin has been emphasized by its continued use as a biological weapon. Currently, there is no FDA approved vaccine or countermeasure against ricin toxin. The successful development of an effective vaccine against ricin toxin may act as a deterrent in the actual use of ricin as a biological weapon and can be used in rapid deployment scenarios in the event of a biological attack. Exposure to small amounts can lead to lung damage if inhaled, rapid onset of nausea, fever, and abdominal pain if ingested. General organ failure leading to death can occur within several days.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal ("GI") diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI graft-versus-host disease ("GVHD"), a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA with the FDA for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a clinical development program with its Lipid Polymer Micelle ("LPM™") oral drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax™, has been shown to be safely tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR also cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.

Contact Information